Annual EBITDA
-$27.66 M
+$5.79 M+17.31%
31 December 2023
Summary:
Tempest Therapeutics annual earnings before interest, taxes, depreciation & amortization is currently -$27.66 million, with the most recent change of +$5.79 million (+17.31%) on 31 December 2023. During the last 3 years, it has fallen by -$1.01 million (-3.81%). TPST annual EBITDA is now -46.59% below its all-time high of -$18.87 million, reached on 31 December 2020.TPST EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$10.13 M
-$1.09 M-12.02%
30 September 2024
Summary:
Tempest Therapeutics quarterly earnings before interest, taxes, depreciation & amortization is currently -$10.13 million, with the most recent change of -$1.09 million (-12.02%) on 30 September 2024. Over the past year, it has dropped by -$3.10 million (-44.18%). TPST quarterly EBITDA is now -139.14% below its all-time high of -$4.24 million, reached on 31 December 2020.TPST Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$33.65 M
-$3.81 M-12.75%
30 September 2024
Summary:
Tempest Therapeutics TTM earnings before interest, taxes, depreciation & amortization is currently -$33.65 million, with the most recent change of -$3.81 million (-12.75%) on 30 September 2024. Over the past year, it has dropped by -$5.99 million (-21.64%). TPST TTM EBITDA is now -543.47% below its all-time high of -$5.23 million, reached on 30 June 2020.TPST TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TPST EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | -44.2% | -21.6% |
| 3 y3 years | -3.8% | -38.0% | -26.3% |
| 5 y5 years | - | - | - |
TPST EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -3.8% | +17.3% | -60.2% | at low | -26.3% | at low |
| 5 y | 5 years | -46.6% | +17.3% | -139.1% | at low | -543.5% | at low |
| alltime | all time | -46.6% | +17.3% | -139.1% | at low | -543.5% | at low |
Tempest Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$10.13 M(+12.0%) | -$33.65 M(+12.8%) |
| June 2024 | - | -$9.04 M(+21.4%) | -$29.84 M(+6.8%) |
| Mar 2024 | - | -$7.45 M(+6.0%) | -$27.94 M(+1.0%) |
| Dec 2023 | -$27.66 M(-17.3%) | -$7.03 M(+11.1%) | -$27.66 M(-4.9%) |
| Sept 2023 | - | -$6.33 M(-11.5%) | -$29.09 M(-6.5%) |
| June 2023 | - | -$7.14 M(-0.3%) | -$31.12 M(-4.4%) |
| Mar 2023 | - | -$7.17 M(-15.2%) | -$32.57 M(-2.6%) |
| Dec 2022 | -$33.45 M | -$8.45 M(+1.2%) | -$33.45 M(+3.4%) |
| Sept 2022 | - | -$8.36 M(-2.7%) | -$32.34 M(+2.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2022 | - | -$8.59 M(+6.7%) | -$31.55 M(+6.4%) |
| Mar 2022 | - | -$8.05 M(+9.7%) | -$29.65 M(+11.3%) |
| Dec 2021 | -$26.65 M(+41.2%) | -$7.34 M(-3.0%) | -$26.65 M(+13.2%) |
| Sept 2021 | - | -$7.57 M(+13.0%) | -$23.54 M(+10.4%) |
| June 2021 | - | -$6.70 M(+32.7%) | -$21.33 M(+7.4%) |
| Mar 2021 | - | -$5.05 M(+19.1%) | -$19.86 M(+34.1%) |
| Dec 2020 | -$18.87 M | -$4.24 M(-20.8%) | -$14.81 M(+40.0%) |
| Sept 2020 | - | -$5.35 M(+2.3%) | -$10.58 M(+102.3%) |
| June 2020 | - | -$5.23 M | -$5.23 M |
FAQ
- What is Tempest Therapeutics annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Tempest Therapeutics?
- What is Tempest Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Tempest Therapeutics?
- What is Tempest Therapeutics quarterly EBITDA year-on-year change?
- What is Tempest Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Tempest Therapeutics?
- What is Tempest Therapeutics TTM EBITDA year-on-year change?
What is Tempest Therapeutics annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of TPST is -$27.66 M
What is the all time high annual EBITDA for Tempest Therapeutics?
Tempest Therapeutics all-time high annual earnings before interest, taxes, depreciation & amortization is -$18.87 M
What is Tempest Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of TPST is -$10.13 M
What is the all time high quarterly EBITDA for Tempest Therapeutics?
Tempest Therapeutics all-time high quarterly earnings before interest, taxes, depreciation & amortization is -$4.24 M
What is Tempest Therapeutics quarterly EBITDA year-on-year change?
Over the past year, TPST quarterly earnings before interest, taxes, depreciation & amortization has changed by -$3.10 M (-44.18%)
What is Tempest Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of TPST is -$33.65 M
What is the all time high TTM EBITDA for Tempest Therapeutics?
Tempest Therapeutics all-time high TTM earnings before interest, taxes, depreciation & amortization is -$5.23 M
What is Tempest Therapeutics TTM EBITDA year-on-year change?
Over the past year, TPST TTM earnings before interest, taxes, depreciation & amortization has changed by -$5.99 M (-21.64%)